MAPT and Alzheimer disease: There were large differences in baseline levels across studies; 6 studies' in AD versus control [13, 15, 18, 20, 22, 23] and 05 studies in DOC versus control have effect size more than pooled estimate [13, 16, 18, 22, 23], signify that dementia patients having higher CSF tau levels than control.